Dashboard
Manage Tickers

CYBNCYBIN INC.

NYSE cybin.com


$ 0.37 $ 0.00 (0 %)    

Thursday, 09-May-2024 15:59:26 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 441.33 $ 0.87 (0.2 %)
DIA $ 394.43 $ 3.95 (1.01 %)
SPY $ 520.56 $ 3.37 (0.65 %)
TLT $ 90.69 $ 0.50 (0.55 %)
GLD $ 216.93 $ 3.35 (1.57 %)
$ 0.3738
$ 0.36
$ 0.00 x 0
$ 0.48 x 400
$ 0.36 - $ 0.37
$ 0.21 - $ 0.74
1,488,195
na
72.27M
$ 0.50
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

pot-company-gets-license-to-open-psilocybin-service-center-the-sacred-mushroom-in-oregon
Pot Company Gets License To Open Psilocybi...
05/09/2024 13:29:42

Core News & Articles
"FDA Expert Committee Will Review MDMA-Ass...
05/07/2024 15:54:11

https://www.marijuanamoment.net/fda-expert-committee-will-review-mdma-assisted-therapy-for-ptsd-next-month/The Food and Drug Ad...

cybin-provides-corporate-update-and-highlights-upcoming-clinical-milestones-initiation-of-pivotal-cyb003-phase-3-study-in-mdd-expected-in-mid-2024-phase-2-topline-efficacy-and-safety-results-for-cyb004-in-generalized-anxiety-disorder-expected-q4-2024
Cybin Provides Corporate Update And Highli...
05/06/2024 12:42:05

- Recent U.S. $150 Million funding round lead by a syndicate of leading biopharmaceutical institutional investors supports adva...

cybin-announces-grant-of-additional-us-patent-in-support-of-its-cyb003-breakthrough-therapy-program-for-major-depressive-disorder
Cybin Announces Grant Of Additional US Pat...
04/16/2024 11:35:02

psychedelics-headlines-a-form-of-life-treating-chronic-pain-microdosing-and-more
Psychedelics Headlines: A Form Of Life, Tr...
03/30/2024 12:57:44

psyched-lsd-psilocybin-as-breakthrough-therapies-14m-fed-grant-for-ibogaine-indianas-research-and-more
Psyched: LSD, Psilocybin As Breakthrough T...
03/20/2024 18:49:36

cybin-says-it-initiated-phase-2-proof-of-concept-study-of-cyb004-in-generalized-anxiety-disorder
Cybin Says It Initiated Phase 2 Proof-of-C...
03/15/2024 11:34:43

Core News & Articles
Reported Earlier, 'Indiana Lawmakers Send ...
03/14/2024 16:42:38

https://www.marijuanamoment.net/indiana-lawmakers-send-psilocybin-research-funding-bill-to-governor/   The Indiana legislatur...

cybin-announces-end-of-phase-2-meeting-with-fda-for-cyb003-in-major-depressive-disorder-and-phase-3-program-design
Cybin Announces End-of-Phase 2 Meeting wit...
03/14/2024 11:32:16

Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company co...

fda-grants-cybin-breakthrough-therapy-status-for-major-depression-psilocybin-therapy-company-announces-positive-clinical-data--canadian-150m-private-placement
FDA Grants Cybin Breakthrough Therapy Stat...
03/13/2024 15:33:50

hc-wainwright--co-maintains-buy-on-cybin-maintains-5-price-target
HC Wainwright & Co. Maintains Buy on Cybin...
03/13/2024 15:32:37

HC Wainwright & Co. analyst Patrick Trucchio maintains Cybin (AMEX:CYBN) with a Buy and maintains $5 price target.

cybin-receives-fda-breakthrough-therapy-designation-for-its-novel-psychedelic-molecule-cyb003-and-announces-positive-four-month-durability-data-in-major-depressive-disorder
Cybin Receives FDA Breakthrough Therapy De...
03/13/2024 10:01:36

psyched-new-evidence-shows-psilocybin-as-anxiety-therapy-open-source-learning-for-therapists-enverics-licensing-deals-and-more
Psyched: New Evidence Shows Psilocybin As ...
03/04/2024 18:48:15

cybin-inc-q3-earnings-clinical-advances-amid-financial-loss
Cybin Inc. Q3 Earnings: Clinical Advances ...
02/16/2024 19:07:34

The TDR Three Key Takeaways:

hc-wainwright--co-reiterates-buy-on-cybin-maintains-5-price-target
HC Wainwright & Co. Reiterates Buy on Cybi...
02/15/2024 17:41:33

HC Wainwright & Co. analyst Patrick Trucchio reiterates Cybin (AMEX:CYBN) with a Buy and maintains $5 price target.

psychedelics-headlines-trauma-informed-care-valentines-day--mdma-academics-on-drugs-and-more
Psychedelics Headlines: Trauma-Informed Ca...
02/15/2024 15:55:16

cybin-says-net-loss-was-c303-million-for-q3-cash-totaled-c390-million-as-of-december-31-2023
Cybin Says Net Loss Was C$30.3 Million For...
02/14/2024 12:57:21

Core News & Articles
'FDA Grants Priority Review Of MDMA-Assist...
02/12/2024 16:38:30

https://www.marijuanamoment.net/fda-grants-priority-review-of-mdma-assisted-therapy-for-ptsd-psychedelics-drug-development-comp...

cybin-reveals-grant-of-two-additional-patents-in-japan-in-support-of-its-dmt-program
Cybin Reveals Grant Of Two Additional Pate...
02/07/2024 12:33:42

The patents, which are expected to provide exclusivity until at least 2040 and 2041, respectively, include protection for a syn...

psyched-suggestibility-and-psychedelics-effects-eus-7m-research-fund-australias-treatment-delivery-bz-podcast-and-more
Psyched: Suggestibility And Psychedelics' ...
01/27/2024 15:00:18

New study finds suggestibility plays a role in antidepressant effects of psilocybin therapy. EU invests 6.5M euros in psychedel...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION